KALARIS THERAPEUTICS, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
KALARIS THERAPEUTICS, INC. (KLRS) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $644.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-11
- KALARIS THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $644.00K, a 8.97% increase year-over-year.
- KALARIS THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $580.00K, a 55.08% increase year-over-year.
- KALARIS THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $638.00K, a 143.51% increase year-over-year.
- KALARIS THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $591.00K, a 83.54% increase year-over-year.
- KALARIS THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $1.94M, a 116.31% increase from fiscal 2024.
- KALARIS THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $895.00K, a 97.81% decline from fiscal 2023.
- KALARIS THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $40.78M, a 1.30% decline from fiscal 2022.
- KALARIS THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $41.31M, a 6.05% decline from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month as first filed | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $644.00K 10-Q · filed 2026-08-11 | $1.22M derived: sum of 2 quarters · filed 2026-08-11 | ||||
| 2026-03-31 | $580.00K 10-Q · filed 2026-08-11 | |||||
| 2025-12-31 | $1.94M 10-K · filed 2026-03-17 | |||||
| 2025-09-30 | $638.00K 10-Q · filed 2025-11-12 | $1.23M derived: sum of 2 quarters · filed 2026-08-11 | $1.60M derived: sum of 3 quarters · filed 2026-08-11 | |||
| 2025-06-30 | $591.00K 10-Q · filed 2026-08-11 | $965.00K derived: sum of 2 quarters · filed 2026-08-11 | ||||
| 2025-03-31 | $374.00K 10-Q · filed 2026-08-11 | |||||
| 2024-12-31 | $895.00K 10-K · filed 2026-03-17 | $26.35M 10-K · filed 2025-03-07 | ||||
| 2024-09-30 | $262.00K 10-Q · filed 2025-11-12 | $4.95M 10-Q · filed 2024-11-12 | $584.00K derived: sum of 2 quarters · filed 2025-11-12 | $615.00K derived: sum of 3 quarters · filed 2025-11-12 | ||
| 2024-06-30 | $322.00K 10-Q · filed 2025-11-12 | $5.91M 10-Q · filed 2024-08-09 | $353.00K derived: sum of 2 quarters · filed 2025-11-12 | |||
| 2024-03-31 | $31.00K 10-Q · filed 2025-11-12 | $5.03M 10-Q · filed 2024-05-13 | ||||
| 2023-12-31 | $40.78M 10-K · filed 2025-03-07 | |||||
| 2023-09-30 | $10.47M 10-Q · filed 2024-11-12 | $20.76M derived: sum of 2 quarters · filed 2024-11-12 | $30.79M derived: sum of 3 quarters · filed 2024-11-12 | |||
| 2023-06-30 | $10.29M 10-Q · filed 2024-11-12 | $20.32M derived: sum of 2 quarters · filed 2024-11-12 | ||||
| 2023-03-31 | $10.03M 10-Q · filed 2024-11-12 | |||||
| 2022-12-31 | $41.31M 10-K · filed 2024-03-15 | |||||
| 2022-09-30 | $10.86M 10-Q · filed 2023-11-02 | $21.81M derived: sum of 2 quarters · filed 2023-11-02 | $32.27M derived: sum of 3 quarters · filed 2023-11-02 | |||
| 2022-06-30 | $10.95M 10-Q · filed 2023-11-02 | $21.42M derived: sum of 2 quarters · filed 2023-11-02 | ||||
| 2022-03-31 | $10.47M 10-Q · filed 2023-11-02 | |||||
| 2021-12-31 | $43.98M 10-K · filed 2023-02-15 | |||||
| 2021-09-30 | $10.29M 10-Q · filed 2022-11-03 | $20.01M derived: sum of 2 quarters · filed 2022-11-03 | $28.11M derived: sum of 3 quarters · filed 2022-11-03 | |||
| 2021-06-30 | $9.73M 10-Q · filed 2022-11-03 | $17.83M derived: sum of 2 quarters · filed 2022-11-03 | ||||
| 2021-03-31 | $8.10M 10-Q · filed 2022-11-03 | |||||
| 2020-12-31 | $9.43M 10-K · filed 2022-02-10 | |||||
| 2020-09-30 | $3.86M 10-Q · filed 2021-11-05 | $4.35M derived: sum of 2 quarters · filed 2021-11-05 | $5.00M derived: sum of 3 quarters · filed 2021-11-05 | |||
| 2020-06-30 | $492.00K 10-Q · filed 2021-11-05 | $1.14M derived: sum of 2 quarters · filed 2021-11-05 | ||||
| 2020-03-31 | $646.00K 10-Q · filed 2021-11-05 | |||||
| 2019-12-31 | $2.89M 10-K · filed 2021-02-12 | |||||
| 2019-09-30 | $596.00K 10-Q · filed 2020-11-10 | $2.04M derived: sum of 2 quarters · filed 2020-11-10 | $2.27M derived: sum of 3 quarters · filed 2020-11-10 | |||
| 2019-06-30 | $1.44M 10-Q · filed 2020-11-10 | $1.67M derived: sum of 2 quarters · filed 2020-11-10 | ||||
| 2019-03-31 | $231.00K 10-Q · filed 2020-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |